icu medical inc. - ICUI
ICUI
Close Chg Chg %
149.64 4.52 3.02%
Closed Market
154.16
+4.52 (3.02%)
Volume: 223.28K
Last Updated:
Feb 6, 2026, 4:00 PM EDT
Company Overview: icu medical inc. - ICUI
ICUI Key Data
| Open $151.01 | Day Range 149.05 - 154.79 |
| 52 Week Range 107.02 - 165.17 | Market Cap $3.70B |
| Shares Outstanding 24.69M | Public Float 23.92M |
| Beta 0.80 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.31 |
| Yield 0.00% | Dividend $1.50 |
| EX-DIVIDEND DATE Mar 18, 2002 | SHORT INTEREST N/A |
| AVERAGE VOLUME 241.48K |
ICUI Performance
| 1 Week | 2.84% | ||
| 1 Month | 0.76% | ||
| 3 Months | 9.99% | ||
| 1 Year | -1.59% | ||
| 5 Years | -30.07% |
ICUI Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
7
Full Ratings ➔
About icu medical inc. - ICUI
ICU Medical, Inc. engages in the provision of innovative medical products used in infusion therapy and critical care applications. Its product portfolio includes IV smart pumps, sets, connectors, closed system transfer devices for hazardous drugs, sterile IV solutions, cardiac monitoring systems, along with pain management and safety software technology designed to help meet clinical, safety and workflow goals. The company was founded by George A. Lopez in 1984 and is headquartered in San Clemente, CA.
ICUI At a Glance
ICU Medical, Inc.
951 Calle Amanecer
San Clemente, California 92673-6212
| Phone | 1-949-366-2183 | Revenue | 2.38B | |
| Industry | Medical Specialties | Net Income | -117,688,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 5.323% | |
| Fiscal Year-end | 12 / 2025 | Employees | 15,000 | |
| View SEC Filings |
ICUI Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.591 |
| Price to Book Ratio | 1.936 |
| Price to Cash Flow Ratio | 18.55 |
| Enterprise Value to EBITDA | 15.27 |
| Enterprise Value to Sales | 2.151 |
| Total Debt to Enterprise Value | 0.321 |
ICUI Efficiency
| Revenue/Employee | 158,604.333 |
| Income Per Employee | -7,845.867 |
| Receivables Turnover | 12.704 |
| Total Asset Turnover | 0.554 |
ICUI Liquidity
| Current Ratio | 2.576 |
| Quick Ratio | 1.525 |
| Cash Ratio | 0.555 |
ICUI Profitability
| Gross Margin | 34.539 |
| Operating Margin | 3.965 |
| Pretax Margin | -2.775 |
| Net Margin | -4.947 |
| Return on Assets | -2.743 |
| Return on Equity | -5.757 |
| Return on Total Capital | -3.262 |
| Return on Invested Capital | -3.226 |
ICUI Capital Structure
| Total Debt to Total Equity | 83.589 |
| Total Debt to Total Capital | 45.531 |
| Total Debt to Total Assets | 39.076 |
| Long-Term Debt to Equity | 80.141 |
| Long-Term Debt to Total Capital | 43.653 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Icu Medical Inc. - ICUI
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 1.32B | 2.28B | 2.26B | 2.38B | |
Sales Growth
| +3.56% | +72.92% | -0.76% | +5.32% | |
Cost of Goods Sold (COGS) incl D&A
| 837.86M | 1.61B | 1.53B | 1.56B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 99.29M | 258.80M | 250.68M | 240.86M | |
Depreciation
| 75.49M | 119.40M | 118.58M | 106.56M | |
Amortization of Intangibles
| 23.80M | 139.40M | 132.10M | 134.30M | |
COGS Growth
| +3.40% | +92.59% | -5.36% | +1.98% | |
Gross Income
| 478.45M | 662.53M | 731.73M | 821.71M | |
Gross Income Growth
| +3.85% | +38.47% | +10.44% | +12.30% | |
Gross Profit Margin
| +36.35% | +29.11% | +32.39% | +34.54% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 340.49M | 677.68M | 692.04M | 727.38M | |
Research & Development
| 47.50M | 92.98M | 85.34M | 88.61M | |
Other SG&A
| 292.99M | 584.69M | 606.69M | 638.76M | |
SGA Growth
| +4.16% | +99.03% | +2.12% | +5.11% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 18.16M | 39.33M | 25.01M | 54.44M | |
EBIT after Unusual Expense
| 119.80M | (54.48M) | 14.68M | 39.89M | |
Non Operating Income/Expense
| 4.37M | 17.82M | 42.33M | 27.95M | |
Non-Operating Interest Income
| 2.80M | 4.43M | 7.51M | 10.79M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 980.00K | 77.76M | 135.31M | 133.85M | |
Interest Expense Growth
| -44.10% | +7,834.29% | +74.02% | -1.07% | |
Gross Interest Expense
| 980.00K | 77.76M | 135.31M | 133.85M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 123.19M | (114.41M) | (78.30M) | (66.01M) | |
Pretax Income Growth
| +26.35% | -192.88% | +31.56% | +15.69% | |
Pretax Margin
| +9.36% | -5.03% | -3.47% | -2.77% | |
Income Tax
| 20.05M | (40.12M) | (48.64M) | 51.68M | |
Income Tax - Current - Domestic
| 24.09M | 7.93M | (3.20M) | 20.84M | |
Income Tax - Current - Foreign
| 7.24M | 12.92M | 26.04M | 25.16M | |
Income Tax - Deferred - Domestic
| (9.97M) | (53.25M) | (57.70M) | 16.14M | |
Income Tax - Deferred - Foreign
| (1.31M) | (7.72M) | (13.78M) | (10.48M) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 103.14M | (74.29M) | (29.66M) | (117.69M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 103.14M | (74.29M) | (29.66M) | (117.69M) | |
Net Income Growth
| +18.72% | -172.03% | +60.08% | -296.86% | |
Net Margin Growth
| +7.84% | -3.26% | -1.31% | -4.95% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 103.14M | (74.29M) | (29.66M) | (117.69M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 103.14M | (74.29M) | (29.66M) | (117.69M) | |
EPS (Basic)
| 4.8635 | -3.1124 | -1.231 | -4.8257 | |
EPS (Basic) Growth
| +17.05% | -164.00% | +60.45% | -292.01% | |
Basic Shares Outstanding
| 21.21M | 23.87M | 24.09M | 24.39M | |
EPS (Diluted)
| 4.7351 | -3.1124 | -1.231 | -4.8257 | |
EPS (Diluted) Growth
| +17.69% | -165.73% | +60.45% | -292.01% | |
Diluted Shares Outstanding
| 21.78M | 23.87M | 24.09M | 24.39M | |
EBITDA
| 237.26M | 243.65M | 290.37M | 335.19M | |
EBITDA Growth
| +3.76% | +2.70% | +19.17% | +15.43% | |
EBITDA Margin
| +18.02% | +10.70% | +12.85% | +14.09% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 181.40 | |
| Number of Ratings | 7 | Current Quarters Estimate | 1.773 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | 7.968 | |
| Last Quarter’s Earnings | 1.68 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 7.572 | Next Fiscal Year Estimate | 9.13 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 4 | 4 | 6 | 6 |
| Mean Estimate | 1.77 | 1.97 | 7.97 | 9.13 |
| High Estimates | 1.80 | 2.10 | 8.00 | 9.45 |
| Low Estimate | 1.73 | 1.86 | 7.93 | 8.89 |
| Coefficient of Variance | 1.62 | 5.11 | 0.31 | 2.55 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 5 | 5 | 5 |
| OVERWEIGHT | 0 | 0 | 1 |
| HOLD | 2 | 2 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Buy |
SEC Filings for Icu Medical Inc. - ICUI
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Icu Medical Inc. - ICUI
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Nov 26, 2025 | Daniel Woolson VP, GM-Infusion Capital | 11,297 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $152.35 per share | 1,721,097.95 |
| May 29, 2025 | Christian B. Voigtlander Chief Operating Officer | 10,458 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $96.83 per share | 1,012,648.14 |
| May 29, 2025 | Christian B. Voigtlander Chief Operating Officer | 5,513 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $131 per share | 722,203.00 |
| May 29, 2025 | Christian B. Voigtlander Chief Operating Officer | 11,073 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $96.83 per share | 1,072,198.59 |
| May 29, 2025 | Christian B. Voigtlander Chief Operating Officer | 6,088 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $128.5 per share | 782,308.00 |
| May 29, 2025 | Christian B. Voigtlander Chief Operating Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 29, 2025 | Christian B. Voigtlander Chief Operating Officer | 5,560 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 17, 2025 | Vivek Jain Chairman and CEO; Director | 15,848 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2025 | Virginia Sanzone VP, General Counsel | 5,555 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 11, 2025 | Brian M. Bonnell Chief Financial Officer | 27,100 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 11, 2025 | Virginia Sanzone VP, General Counsel | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 11, 2025 | Virginia Sanzone VP, General Counsel | 6,360 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $141.97 per share | 902,929.20 |
| Mar 11, 2025 | Virginia Sanzone VP, General Counsel | 8,119 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 11, 2025 | Virginia Sanzone VP, General Counsel | 4,930 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $141.97 per share | 699,912.10 |
| Mar 11, 2025 | Ben Sousa Chief Information Officer | 7,098 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2025 | Ben Sousa Chief Information Officer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 11, 2025 | Ben Sousa Chief Information Officer | 2,446 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 11, 2025 | Ben Sousa Chief Information Officer | 1,489 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $141.97 per share | 211,393.33 |
| Mar 11, 2025 | Daniel Woolson VP, GM-Infusion Capital | 9,061 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 11, 2025 | Vivek Jain Chairman and CEO; Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |